Literature DB >> 28866023

Where Do Transrectal Ultrasound- and Magnetic Resonance Imaging-guided Biopsies Miss Significant Prostate Cancer?

Lars Boesen1, Nis Nørgaard2, Vibeke Løgager3, Ingegerd Balslev4, Henrik S Thomsen3.   

Abstract

OBJECTIVE: To identify the location of missed significant prostate cancer (sPCa) lesions by transrectal ultrasound-guided biopsy (TRUSbx) and multiparametric magnetic resonance imaging-guided biopsy (mpMRIbx) in men undergoing repeat biopsies.
MATERIALS AND METHODS: A total of 289 men with prior negative TRUSbx underwent multiparametric magnetic resonance imaging. The location of any suspicious lesion was registered and scored using Prostate Imaging Reporting and Data System version 1 classification according to the likelihood of being sPCa. All patients underwent repeat transrectal ultrasound-guided biopsy (reTRUSbx) and targeted mpMRIbx (image fusion) of any suspicious lesion. Biopsy results were compared and the locations of missed sPCa lesions were registered. Cancer significance was defined as (1) any core with a Gleason score of >6, (2) cancer core involvement of ≥50% and for reTRUSbx on patient level, and (3) the presence of ≥3 positive cores.
RESULTS: Of the 289 patients, prostate cancer was detected in 128 (44%) with 88 (30%) having sPCa. Overall, 165 separate prostate cancer lesions were detected with 100 being sPCa. Of these, mpMRIbx and reTRUSbx detected 90% (90/100) and 68% (68/100), respectively. The majority of sPCa lesions (78%) missed by primary TRUSbx were located either anteriorly or in the apical region. Missed sPCa lesions at repeat biopsy were primarily located anteriorly (84%) for reTRUSbx (n = 27/32) and posterolateral midprostatic (60%) for mpMRIbx (n = 6/10).
CONCLUSION: Both TRUSbx and mpMRIbx missed sPCa lesions in specific segments of the prostate. Missed sPCa lesions at repeat biopsy were primarily located anteriorly for TRUSbx and posterolateral midprostatic for mpMRIbx. Localization of these segments may improve biopsy techniques in men undergoing repeat biopsies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28866023     DOI: 10.1016/j.urology.2017.08.028

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

Review 1.  Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review.

Authors:  Elizabeth E Ellis; Thomas P Frye
Journal:  Ther Adv Urol       Date:  2022-07-18

2.  Bi-parametric MRI/TRUS fusion targeted repeat biopsy after systematic 10-12 core TRUS-guided biopsy reveals more significant prostate cancer especially in anteriorly located tumors.

Authors:  Michael Häggman; Pär Dahlman; Mats Ahlberg; Per Liss; Rafaele Cantera Ahlman; Anca Dragomir; Sam Ladjevardi
Journal:  Acta Radiol Open       Date:  2022-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.